Close this search box.

We are creating some awesome events for you. Kindly bear with us.

UQ Partners Global Biotech Firm for MRNA Tech Research

The University of Queensland has been selected as one of the first launch institutions in the world to partner with a US pharmaceutical and biotechnology company to research and develop vaccines to tackle the world’s greatest global public health threats.

The partnership, brokered by two of the University’s leading researchers Professor Mark Walker and Professor Paul Young, will allow UQ scientists access to Moderna’s mRNA platform to develop mRNA vaccines for neglected and emerging viruses.

Professor Young stated that the partnership is a coup for UQ with advances in vaccine delivery potentially saving thousands of lives in developing countries. It is also recognised that UQ is a centre of excellence in vaccine research and discovery. It was noted that there were at least 10 disease research projects underway at UQ that could benefit immediately from the mRNA Access partnership.

The biotech company will set up a portal where researchers in this collaborative agreement will have access to their mRNA technology to target these identified pathogens, he said. The partnership will focus on diseases that have the potential to emerge as a future pandemic and diseases that are already a problem in low- and middle-income countries, like dengue, malaria, tuberculosis and zika virus.

Professor Walker said it was a crucial collaboration. He noted that what they will be getting from them is a “full package – we would provide the sequence; they would provide back to us a formulated vaccine that we would put into pre-clinical studies,” he said. UQ brings disease-specific expertise to be able to design and test vaccines and demonstrate efficacy – those are the things that UQ does very well.”

Professor Walker said the partnership would speed up the production of new vaccines. This is rapid turnaround technology and the identification of a new vaccine to clinical use stage could happen in as little as 100 days, he noted. There is no doubt that the production of vaccines to target these diseases will be delivered more quickly by this collaboration.

Professor Young said the partnership could also result in commercial opportunities. Several UQ researchers have already been exploring mRNA vaccine delivery and it’s quite a challenging pathway to get right, so having this partnership is going to make a significant change to the way we can progress these studies forward, he said.

For example, if the mRNA technology can be successfully applied to generate an effective dengue vaccine, something that has been a goal for many decades, then not only will we be addressing a long-term global disease threat but also helping to support our local biotechnology industry. Professor Walker added that there could also be applications for bacterial diseases which are resistant to antibiotics.

While much of the recent narrative has been around viral and pandemic vaccines, targeting anti-microbial resistant bacterial diseases is another important goal of this partnership. Researchers are starting to think about trying to resolve this growing global threat via vaccines instead of antibiotics.

The Global mRNA Vaccines and Therapeutics Market is forecast to grow. The market growth is essentially attributed to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.

Additionally, the inability of the traditional vaccine approaches to perform at a critical time boosts the market growth. Further, technological advancements support the growth of the market as mRNA vaccines and therapeutics are developed with the help of advanced technologies so that these vaccines are highly effective in crucial times.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.